GlassScriptPhysician profile
Nausheen Hasan
NPI 1245321207
$8,764.77
in general payments reported to CMS, 2019-2025
40 companies · $843 in 2025
The $843 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $1,416 · 2021: $1,392 · 2022: $1,267 · 2023: $1,168 · 2024: $1,196 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,206.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,188.19 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $798.57 | 2020-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $571.76 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| E.R. Squibb & Sons, L.L.C. | $557.88 | 2019-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $539.92 | 2019-2025 | Airsupra, Farxiga |
| Sunovion Pharmaceuticals INC. | $462.21 | 2019-2022 | |
| Ucb, INC. | $417.54 | 2020-2025 | Briviact, Fintepla, Nayzilam |
| Janssen Pharmaceuticals, INC | $409.51 | 2019-2024 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $384.08 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $324.00 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $319.65 | 2021-2024 | |
| Pfizer INC. | $252.84 | 2019-2025 | |
| Abbvie INC. | $245.78 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.94 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $213.29 | 2023-2025 | Cologuard Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nausheen Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.